Eli Lilly has stopped providing 340B drug discounts to hospitals that did not comply with its claims data submission requirements. The company had issued a June 8 ultimatum to an unspecified group of hospitals that refused to follow the data policy it established in February. Hospital industry groups have condemned the action as unlawful and called for federal intervention.
The move deepens a long-running dispute between drug manufacturers and covered entities over data sharing in the 340B program. It highlights the manufacturers’ push for greater transparency on dispensing and contract pharmacy claims, what they describe as a safeguard against duplicate discounts and misuse. Hospital groups argue the opposite, saying manufacturers are imposing conditions outside federal authority. The next development is expected to be regulatory. How the Biden administration’s health agencies, or the courts, decide to act could determine whether similar manufacturer mandates spread beyond this round.
Viewed across the market, Lilly’s stance signals a shift among drugmakers toward firmer control of 340B economics and the curbing of what they describe as leakage. Should regulators allow this approach to continue, comparable data requirements may appear elsewhere, tightening day‑to‑day operations for hospital pharmacy networks. Investors and payers will be watching to see how far enforcement reaches, whether it reshapes 340B margins, and how that ripples through manufacturer pricing strategies in the longer horizon.
